Six IPOs debuted this week, raising a combined $1.8 billion. Four SPACs also listed. One IPO and seven SPACs submitted initial filings. Leading the pack, electric aircraft manufacturer Beta Technologies (BETA) priced its upsized IPO above the range to raise...read more
Evommune, a Phase 2 biotech developing therapies for chronic inflammatory diseases, raised $150 million by offering 9.4 million shares at $16, the midpoint of the range of $15 to $17. At pricing, Evommune commands a fully diluted market value of $544 million. ...read more
The long-awaited IPO pickup lost some of its steam in October, as the US government shutdown disrupted timelines and delayed deal activity. Twenty-two IPOs raised a combined $3.2 billion, in line with the 10-year historical average by deal count (21) but well...read more
Five sizable IPOs are scheduled for the week ahead, which all launched after the government shutdown began, and are all pricing through the 20-day rule pursuant to Section 8(a) of the Securities Act of 1933. Leading the pack, Beta Technologies (BETA) plans...read more
US IPO Weekly Recap: Beta Technologies leads 6 deal week to open November
Six IPOs debuted this week, raising a combined $1.8 billion. Four SPACs also listed. One IPO and seven SPACs submitted initial filings. Leading the pack, electric aircraft manufacturer Beta Technologies (BETA) priced its upsized IPO above the range to raise...read more
Chronic inflammatory disease biotech Evommune prices IPO at $16 midpoint
Evommune, a Phase 2 biotech developing therapies for chronic inflammatory diseases, raised $150 million by offering 9.4 million shares at $16, the midpoint of the range of $15 to $17. At pricing, Evommune commands a fully diluted market value of $544 million. ...read more
Renaissance Capital's October IPO Market Update
The long-awaited IPO pickup lost some of its steam in October, as the US government shutdown disrupted timelines and delayed deal activity. Twenty-two IPOs raised a combined $3.2 billion, in line with the 10-year historical average by deal count (21) but well...read more
US IPO Week Ahead: Beta Technologies leads flurry of debuts as shutdown rolls on
Five sizable IPOs are scheduled for the week ahead, which all launched after the government shutdown began, and are all pricing through the 20-day rule pursuant to Section 8(a) of the Securities Act of 1933. Leading the pack, Beta Technologies (BETA) plans...read more